I am a medical oncologist with special expertise in lymphoma, and former Chief of Memorial Sloan Kettering’s Lymphoma Service. I am a member of a close-knit team that provides compassionate, multidisciplinary care to patients with lymphoma.
I have helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies I am evaluating the benefits of novel combinations of agents. In another area of research I am working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. I have published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology, and Clinical Cancer Research.
I am involved in several national organizations that provide information about lymphoma treatment and fund laboratory and clinical research. I am chairperson of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network and vice chairperson of the Lymphoma Core Committee of the Cancer and Leukemia Group B. I am also a member of the scientific advisory board of the Lymphoma Research Foundation.
- Clinical Expertise: Hodgkin and non-Hodgkin Lymphomas: Lymphocytic Lymphomas, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Immunotherapy for Lymphoma
- Languages Spoken: English
- Education: MD, Harvard Medical School
- Residencies: Stanford University Medical Center
- Fellowships: Stanford University Medical Center
- Board Certifications: Internal Medicine; Medical Oncology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more